Market Access Views & Analysis

Views & Analysis

The 4 biggest pharma market access stories of 2019

What events have defined the market access landscape in 2019, and what trends will shape 2020? We dive into the pharmaphorum archives to find out.

Views & Analysis

Growing Statistic Financial 2019 Against United Kingdom Flag

An alternative set of metrics for the UK’s pricing and acces...

Leela Barham takes a look at alternative ways pharma and the UK government could measure progress for the VPAS.

Views & Analysis

15 pharma trends for 2020

Real world evidence, patient centricity and new digital experiences are among the top 15 trends set to change clinical research and treatment commercialisation in 2020, according to Syneos

Views & Analysis

How does prevalence affect pricing of rare disease drugs?

New research from CRA looks at the relationship between rarity of a disease and the price countries are willing to pay for drugs to treat them.

Views & Analysis

The concept of a new year with new ideas. Hand showing light bulb with luminous numbers 2020.

Nine for 2019: how did we do on our predictions, and what do...

Year-ends prompt reflection, both on what’s happened in the last 12 months and on the year ahead.

Views & Analysis

Q&A: Zulf Masters on emerging markets

UK-based Masters Speciality Pharma focuses on supplying medicines to developing countries where access to treatments is limited – partnering with big pharma firms such as Novartis, Alex

The 4 biggest pharma market access stories of 2019

An alternative set of metrics for the UK’s pricing and acces...

15 pharma trends for 2020

How does prevalence affect pricing of rare disease drugs?

Nine for 2019: how did we do on our predictions, and what do...

Q&A: Zulf Masters on emerging markets

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks